Amplia Therapeutics has used one of the world’s largest oncology stages to sharpen its case for narmafotinib, presenting mature data from its ACCENT trial that suggest the drug could meaningfully shift outcomes in one of the most difficult-to-treat cancers. …
Amplia positions narmafotinib as a potential step change in pancreatic cancer
April 22, 2026 Australian Biotech
Latest Video
New Stories
-
The private market might do what two decades of PBS reform attempts couldn't
October 12, 2026 - - Latest News -
The full set of numbers tell the story and reveal the massive funding shortfall
October 12, 2026 - - Latest News -
Private prescription market heads towards $4 billion as PBS spending stalls
October 12, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News